Fenwick & West represented Morphic Holdings, Inc. in the transaction, and Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY) announced...
Eli Lilly’s $3.2 Billion Acquisition of Morphic Holdings
Eli Lilly’s $1.4 Billion Acquisition of POINT Biopharma
Kirkland & Ellis LLP is acting as legal counsel to Lilly, while Skadden, Arps, Slate, Meagher & Flom LLP is acting as legal counsel to POINT...
Eli Lilly’s $1.925 Billion Acquisition of Versanis Bio
Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
Eli Lilly’s $2.4 Billion Pending Acquisition of DICE THerapeutics
Fenwick & West LLP represented DICE Therapeutics, Inc. in the transaction, while Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY)...
Amphastar’s $1.075 Billion Acquisition of BAQSIMI from Eli Lilly
Wilson, Sonsini is acting as legal counsel to Amphastar. Kirkland & Ellis and Covington & Burling are acting as legal counsel to Lilly. In an effort...
Eli Lilly’s $487 Million Acquisition of Akouos
Kirkland & Ellis represented Lilly, while Wilmer Cutler Pickering Hale and Dorr represented Akouos in the transaction. Eli Lilly and Company (NYSE: LLY) announced its acquisition...
Eli Lilly’s Collaboration Agreement With Evotec
Morgan Lewis represented Eli Lilly and Company on the deal. The collaboration leverages Evotec’s extensive experience and track record of delivering in the field of metabolic...
Eli Lilly’s Collaboration Agreement With Abbisko Therapeutics Co. Ltd.
Morgan Lewis represented Eli Lilly and Company on the deal. Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), has entered into a...
Eli Lilly and Company’s Framework Agreement With The EU Commission For COVID-19 Treatment
Hogan Lovells advised Eli Lilly and Company on the matter. Eli Lilly and Company was involved in a tender process and associated framework agreement with the...